Quality of life in non-metastasic colorectal cancer patients in FOLFOX or XELOX therapy
Objective To evaluate and to compare quality of life of patients with non- metastasic colorectal cancer treated either with FOLFOX or with XELOX scheme. Method: Descriptive prospective study during 24 months (October 2015- October 2017) for patients with non-metastasic colorectal cancer in chemoth...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-03-01
|
| Series: | Farmacia Hospitalaria |
| Subjects: | |
| Online Access: | http://www.aulamedica.es/fh/pdf/11156.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846093779404062720 |
|---|---|
| author | Julia Sánchez-Gundín Ana María Fernández-Carballido Ana Isabel Torres-Suárez Dolores Barreda-Hernández |
| author_facet | Julia Sánchez-Gundín Ana María Fernández-Carballido Ana Isabel Torres-Suárez Dolores Barreda-Hernández |
| author_sort | Julia Sánchez-Gundín |
| collection | DOAJ |
| description | Objective To evaluate and to compare quality of life of patients with non- metastasic colorectal cancer treated either with FOLFOX or with XELOX scheme.
Method: Descriptive prospective study during 24 months (October 2015- October 2017) for patients with non-metastasic colorectal cancer in chemotherapy adyuvant treatment. EORTC QLQ-C30 questionnaire was filled by patients at the beginning and at week 12 of adjuvant treatment.
Variables collected: exposure (chemotherapeutic scheme administered), control (demographic data, disease data, treatment data) and response (scores obtained from the questionnaire). The data statistical analysis was carried out with the SPSS® 15.0 programme.
Results: 30 patients were included. Statistically significant differences were found in emotional role item at the middle of the treatment (FOLFOX 92 points vs. XELOX 82 points; p = 0,036). Patients with FOLFOX presented a clinically relevant worsening in terms of daily activities, constipation and insomnia. Patients treated with XELOX a clinically relevant worsening in daily activities, constipation, fatigue, nausea, vomiting, anorexia and diarrhoea were observed.
Conclusions: Patients with XELOX scheme referred to have worse emotionally status in the middle of the adjuvant treatment than patients treated with FOLFOX scheme and presented a worsening in items fatigue, nausea, vomiting, anorexia and diarrhoea. |
| format | Article |
| id | doaj-art-641e335a908e4e8faa1f1cb22f714530 |
| institution | Kabale University |
| issn | 1130-6343 2171-8695 |
| language | English |
| publishDate | 2019-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Farmacia Hospitalaria |
| spelling | doaj-art-641e335a908e4e8faa1f1cb22f7145302025-01-02T16:24:36ZengElsevierFarmacia Hospitalaria1130-63432171-86952019-03-01432566010.7399/fh.11156Quality of life in non-metastasic colorectal cancer patients in FOLFOX or XELOX therapyJulia Sánchez-Gundín 0Ana María Fernández-Carballido 1Ana Isabel Torres-Suárez 2Dolores Barreda-Hernández 3Servicio de Farmacia, Hospital Virgen de la Luz, Cuenca. Departamento de Farmacia y Tecnología Alimentaria, Universidad Complutense de Madrid, Madrid. SpainDepartamento de Farmacia y Tecnología Alimentaria, Universidad Complutense de Madrid, Madrid, Instituto de Farmacia Industrial, Universidad Complutense de Madrid, Madrid. SpainDepartamento de Farmacia y Tecnología Alimentaria, Universidad Complutense de Madrid, Madrid, Instituto de Farmacia Industrial, Universidad Complutense de Madrid, Madrid. SpainServicio de Farmacia, Hospital Virgen de la Luz, Cuenca. SpainObjective To evaluate and to compare quality of life of patients with non- metastasic colorectal cancer treated either with FOLFOX or with XELOX scheme. Method: Descriptive prospective study during 24 months (October 2015- October 2017) for patients with non-metastasic colorectal cancer in chemotherapy adyuvant treatment. EORTC QLQ-C30 questionnaire was filled by patients at the beginning and at week 12 of adjuvant treatment. Variables collected: exposure (chemotherapeutic scheme administered), control (demographic data, disease data, treatment data) and response (scores obtained from the questionnaire). The data statistical analysis was carried out with the SPSS® 15.0 programme. Results: 30 patients were included. Statistically significant differences were found in emotional role item at the middle of the treatment (FOLFOX 92 points vs. XELOX 82 points; p = 0,036). Patients with FOLFOX presented a clinically relevant worsening in terms of daily activities, constipation and insomnia. Patients treated with XELOX a clinically relevant worsening in daily activities, constipation, fatigue, nausea, vomiting, anorexia and diarrhoea were observed. Conclusions: Patients with XELOX scheme referred to have worse emotionally status in the middle of the adjuvant treatment than patients treated with FOLFOX scheme and presented a worsening in items fatigue, nausea, vomiting, anorexia and diarrhoea.http://www.aulamedica.es/fh/pdf/11156.pdfAdyuvant treatmentColorectal cancerFOLFOXQuality of lifeSafetyXELOX |
| spellingShingle | Julia Sánchez-Gundín Ana María Fernández-Carballido Ana Isabel Torres-Suárez Dolores Barreda-Hernández Quality of life in non-metastasic colorectal cancer patients in FOLFOX or XELOX therapy Farmacia Hospitalaria Adyuvant treatment Colorectal cancer FOLFOX Quality of life Safety XELOX |
| title | Quality of life in non-metastasic colorectal cancer patients in FOLFOX or XELOX therapy |
| title_full | Quality of life in non-metastasic colorectal cancer patients in FOLFOX or XELOX therapy |
| title_fullStr | Quality of life in non-metastasic colorectal cancer patients in FOLFOX or XELOX therapy |
| title_full_unstemmed | Quality of life in non-metastasic colorectal cancer patients in FOLFOX or XELOX therapy |
| title_short | Quality of life in non-metastasic colorectal cancer patients in FOLFOX or XELOX therapy |
| title_sort | quality of life in non metastasic colorectal cancer patients in folfox or xelox therapy |
| topic | Adyuvant treatment Colorectal cancer FOLFOX Quality of life Safety XELOX |
| url | http://www.aulamedica.es/fh/pdf/11156.pdf |
| work_keys_str_mv | AT juliasanchezgundin qualityoflifeinnonmetastasiccolorectalcancerpatientsinfolfoxorxeloxtherapy AT anamariafernandezcarballido qualityoflifeinnonmetastasiccolorectalcancerpatientsinfolfoxorxeloxtherapy AT anaisabeltorressuarez qualityoflifeinnonmetastasiccolorectalcancerpatientsinfolfoxorxeloxtherapy AT doloresbarredahernandez qualityoflifeinnonmetastasiccolorectalcancerpatientsinfolfoxorxeloxtherapy |